New combo therapy aims to boost blood health in sickle cell patients
Disease control
Completed
This study tested whether adding a hormone called erythropoietin (EPO) to the standard drug hydroxyurea could safely improve chronic anemia in adults with sickle cell disease. The small, early-phase trial involved 17 participants who were already on stable hydroxyurea treatment. …
Phase: PHASE1, PHASE2 • Sponsor: Julia Xu • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC